A Phase I/II Randomized, Placebo-Control Trial of Palifermin to Prevent Graft-Versus- Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Running head: Palifermin to prevent GVHD